Intended for healthcare professionals

Papers

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosisCommentary: Evaluating disease modifying treatments in multiple sclerosis

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7388.522 (Published 08 March 2003) Cite this as: BMJ 2003;326:522